Nevanac Shortage: What Providers and Prescribers Need to Know in 2026

Patients scheduled for cataract surgery increasingly report difficulty filling Nevanac (nepafenac 0.1% ophthalmic suspension) prescriptions. While no FDA-designated shortage exists as of 2026, the practical reality for many ophthalmology practices is that patients are arriving at pre-op appointments without their eye drops — creating clinical and logistical challenges. This guide is designed to help you get ahead of the issue.

Current Availability Status of Nevanac (2026)

Nevanac is not on the FDA drug shortage database as of 2026. Harrow Eye (the current distributor) continues to supply the medication. The core challenge is structural rather than a manufacturing failure:

Brand-only formulation: No FDA-approved generic for nepafenac 0.1% ophthalmic means pharmacies carry limited inventory at high unit cost ($329–$413/bottle retail)

Inconsistent stocking: Many community pharmacies do not routinely stock Nevanac due to low expected volume and high carrying cost

Payer restrictions: Prior authorization (PA) and step therapy requirements create significant delays, with PA processing times ranging from same-day to several business days

Clinical Implications for Ophthalmology Practices

Patients who cannot obtain their post-operative NSAID eye drops are at elevated risk for:

Cystoid macular edema (CME) — the most common cause of vision loss after uncomplicated cataract surgery

Elevated postoperative intraocular pressure

Suboptimal pain control in the early post-operative period

Patient non-compliance due to unresolved access issues

Evidence-Based Alternatives: Ophthalmic NSAID Options in 2026

Multiple ophthalmic NSAIDs are FDA-approved for post-cataract surgery inflammation. Current options with clinical evidence:

Bromfenac 0.07% (generic, Prolensa): Once-daily dosing; generic available at $80–$200; strong evidence for CME prevention; some network meta-analyses show improved visual acuity vs. nepafenac 0.1% at one month

Ketorolac 0.5% (generic, Acular): Four-times-daily dosing; most cost-effective at $15–$50; widely available; greater risk of stinging; preservative-free formulation (Acuvail 0.45%) available for sensitive patients

Diclofenac 0.1% (generic): Four-times-daily dosing; generic available at $20–$60; long track record; minimal systemic absorption

Nepafenac 0.3% (Ilevro): Once-daily; same mechanism as Nevanac; brand-only but may be stocked at different pharmacy locations

Mechanistic Considerations: Why Nepafenac Is Clinically Distinct

Nepafenac's prodrug design offers theoretical advantages. After topical application, nepafenac penetrates the cornea and is converted by intraocular hydrolases to amfenac — a potent inhibitor of COX-1 and COX-2. Research has shown that nepafenac penetrates the cornea approximately 6 times faster than diclofenac in vitro and provides more complete inhibition of prostaglandin synthesis (approximately 80% vs. 50% for diclofenac) with a longer duration of action (more than 6 hours vs. 3 hours). This prodrug mechanism also limits the active NSAID in the corneal epithelium, potentially reducing stinging and corneal toxicity risk.

For high-risk patients (those with diabetes, history of uveitis, or prior CME), many retinal surgeons continue to prefer nepafenac or bromfenac over ketorolac based on available efficacy data, though head-to-head comparative evidence remains limited.

Practice Recommendations for Managing Nevanac Access Issues

Write prescriptions early: Send Nevanac prescriptions at least 7–10 days before surgery to allow time for prior authorization processing and pharmacy sourcing.

Pre-authorize where possible: If your practice can identify which of your patients' insurance plans require PA for Nevanac, initiate PA with the prescribing request rather than waiting.

Prepare alternative prescriptions: Consider having a second prescription for bromfenac or ketorolac ready at the time of initial contact, to avoid a second call-back if Nevanac is unavailable.

Direct patients to medfinder: medfinder for providers helps patients locate which pharmacies near them have specific medications in stock, reducing the burden on your front office staff.

Patient Counseling Points

Advise patients to shake the Nevanac bottle well before each use — the suspension settles between applications

Remind patients to remove contact lenses before administration and wait at least 15 minutes before reinsertion (the preservative benzalkonium chloride can damage soft contacts)

Caution patients with bleeding disorders or those on anticoagulants (warfarin, apixaban, rivaroxaban) about the potential for increased intraocular bleeding risk

Strongly advise patients not to exceed 14 days of use without clinical re-evaluation, given risk of corneal epithelial breakdown with prolonged topical NSAID use

The Bottom Line for Providers

Nevanac remains a clinically effective post-cataract NSAID in 2026 with no active FDA shortage. Access challenges are structural — brand-only pricing and inconsistent pharmacy stocking — and can be managed proactively. Writing prescriptions early, having alternative NSAID options ready, and directing patients to resources like medfinder can prevent compliance failures and protect post-operative outcomes. See also: How to Help Your Patients Find Nevanac In Stock: A Provider's Guide.